Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shanghai Institute of Liver Diseases, Shanghai, 200032, China.
Inflammation. 2023 Dec;46(6):2102-2119. doi: 10.1007/s10753-023-01865-8. Epub 2023 Jul 19.
Hypoxia and its induced autophagy are involved in the initiation and progression of liver fibrosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recognized as a potential regulator of autophagy. Our previously reported study found that PCSK9 expression increased in liver fibrosis and that anti-PCSK9 treatment alleviated liver injury. This study aimed to investigate the mechanism of anti-PCSK9 treatment on liver fibrosis by inhibiting hypoxia-induced autophagy. Carbon tetrachloride-induced mouse liver fibrosis and mouse hepatocyte line AML12, cultured under the hypoxic condition, were established to undergo PCSK9 inhibition. The degree of liver fibrosis was shown with histological staining. The reactive oxygen species (ROS) generation was detected by flow cytometry. The expression of PCSK9, hypoxia-inducible factor-1α (HIF-1α), and autophagy-related proteins was examined using Western blot. The autophagic flux was assessed under immunofluorescence and transmission electron microscope. The mouse liver samples were investigated via RNA-sequencing to explore the underlying signaling pathway. The results showed that PCSK9 expression was upregulated with the development of liver fibrosis, which was accompanied by enhanced autophagy. In vitro data verified that PCSK9 increased via hypoxia and inflammation, accompanied by the hypoxia-induced autophagy increased. Then, the validation was acquired of the bidirectional interaction of hypoxia-ROS and PCSK9. The hypoxia reversal attenuated PCSK9 expression and autophagy. Additionally, anti-PCSK9 treatment alleviated liver inflammation and fibrosis, reducing hypoxia and autophagy in vivo. In mechanism, the AMPK/mTOR/ULK1 signaling pathway was identified as a target for anti-PCSK9 therapy. In conclusion, anti-PCSK9 treatment could alleviate liver inflammation and fibrosis by regulating AMPK/mTOR/ULK1 signaling pathway to reduce hypoxia-induced autophagy in hepatocytes.
缺氧及其诱导的自噬参与肝纤维化的发生和发展。脯氨酰肽链内切酶枯草溶菌素/柯萨奇蛋白酶 9(PCSK9)已被认为是自噬的潜在调节剂。我们之前的研究发现,PCSK9 在肝纤维化中表达增加,抗 PCSK9 治疗可减轻肝损伤。本研究旨在通过抑制缺氧诱导的自噬来探讨抗 PCSK9 治疗肝纤维化的机制。建立四氯化碳诱导的小鼠肝纤维化模型和缺氧培养的小鼠肝细胞系 AML12,进行 PCSK9 抑制。通过组织学染色显示肝纤维化程度。通过流式细胞术检测活性氧(ROS)的产生。使用 Western blot 检测 PCSK9、缺氧诱导因子-1α(HIF-1α)和自噬相关蛋白的表达。通过免疫荧光和透射电子显微镜评估自噬流。通过 RNA 测序研究小鼠肝组织样本,以探讨潜在的信号通路。结果表明,随着肝纤维化的发展,PCSK9 表达上调,同时自噬增强。体外数据验证了 PCSK9 通过缺氧和炎症增加,伴随着缺氧诱导的自噬增加。然后,验证了缺氧-ROS 和 PCSK9 的双向相互作用。缺氧逆转减弱了 PCSK9 表达和自噬。此外,抗 PCSK9 治疗减轻了肝炎症和纤维化,减少了体内的缺氧和自噬。在机制上,鉴定出 AMPK/mTOR/ULK1 信号通路是抗 PCSK9 治疗的靶点。综上所述,抗 PCSK9 治疗通过调节 AMPK/mTOR/ULK1 信号通路减轻肝炎症和纤维化,减少肝细胞缺氧诱导的自噬。